Symptomatic remission has been defined as a complete or near-complete absence of symptoms. Just as the distinction between remitters and nonremitters among treatment responders has clinical significance, the distinction between a complete and near-complete absence of symptoms itself might be important. Recent studies have reported a high frequency of residual symptoms in patients who are presumably in remission, and this raises questions about how residual symptoms are defined. In the present report from the Rhode Island Methods to Improve Diagnostic Assessment and Services project, we compared the prevalence of residual symptoms based on different cutoff scores on 2 self-report measures of depression and then determined the association between residual symptoms and indices of psychosocial morbidity. We administered the 17-item Hamilton Rating Scale for Depression to 274 psychiatric outpatients diagnosed as having DSM-IV major depressive disorder who were in ongoing treatment. The patients completed the Clinically Useful Depression Outcome Scale (CUDOS) and Quick Inventory of Depressive Symptomatology (QIDS) and measures of psychosocial functioning and quality of life. We examined the frequency of residual symptoms in the 142 patients scoring in the remission range on the Hamilton Rating Scale for Depression. For both the CUDOS and QIDS, the threshold to define symptom presence strongly impacted on the prevalence of residual symptoms. The association between residual symptoms, psychosocial functioning, and quality of life varied according to the threshold used to define the symptoms. On the QIDS, a cutoff of 1 was a more valid indicator of the presence of residual symptoms than a cutoff of 2, whereas on the CUDOS, we recommend a cutoff of 2 be used to indicate the presence of residual symptoms. Examination of the frequency of specific symptoms suggests that the choice of scale might impact on which residual symptoms are considered the most frequent in treatment remitters.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.comppsych.2012.06.010DOI Listing

Publication Analysis

Top Keywords

residual symptoms
44
symptoms
14
residual
11
symptoms defined
8
complete near-complete
8
near-complete absence
8
absence symptoms
8
frequency residual
8
prevalence residual
8
association residual
8

Similar Publications

Ultrasound-guided Transperineal Prostate Thermal Ablation (TPTA) for Benign Prostatic Hyperplasia: Feasibility of an Outpatient Procedure using Radiofrequency Ablation.

Cardiovasc Intervent Radiol

January 2025

Department of Radiology, Universidade Federal de São Paulo (UNIFESP), Rua Dr. Ovidio Pires de Campos, 75, Cerqueira César, São Paulo, SP, 05403-010, Brazil.

Purpose: To evaluate the feasibility, safety, and short-term (3-month) results of transperineal prostate thermal ablation (TPTA) as a minimally invasive outpatient treatment for benign prostatic hyperplasia (BPH).

Materials And Methods: A prospective nonrandomized study of 25 patients with lower urinary tract symptoms secondary to BPH seeking care at 2 interventional radiology centers between March and July 2024. TPTA was performed using a 17G radiofrequency needle with a 10-mm active tip under unconscious sedation combined with bilateral perineal and periprostatic nerve blocks.

View Article and Find Full Text PDF

We aimed to evaluate the incidence of residual shunt after patent foramen ovale (PFO) closure and analyze the anatomical features of PFO to determine the risk factors for significant residual shunt after PFO closure. Ninety-two patients who underwent PFO closure at our center between September 2021 and June 2022 were consecutively enrolled. Transthoracic saline contrast echocardiography was performed at 6 and 12 months postoperatively to evaluate the presence of a significant residual shunt.

View Article and Find Full Text PDF

Objectives: Monitoring minimal residual disease (MRD) and timely intervention are effective strategies for preventing relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adult acute myeloid leukemia (AML). The gene, a pan-leukemia marker, can be used as an indicator for MRD monitoring in AML patients. Currently, there is no unified standard for the intervention timing or treatment threshold based on gene detection after transplantation.

View Article and Find Full Text PDF

Cell-free transcription amplification-based split-type electrochemical sensor using enzyme-linked magnetic microbeads for minimal residual leukemia detection.

Talanta

January 2025

Department of Rehabilitation Medicine, School of Health, Fujian Medical University, Fuzhou, 350122, China; Department of Orthopaedics, Fujian Provincial Institute of Orthopaedics, The First Affiliated Hospital, Fujian Medical University, Fuzhou, 350005, China. Electronic address:

Constrained by detecting techniques, patients with acute promyelocytic leukemia (APL) are often confronted with minimal residual disease (MRD) and a high risk of relapse. Thus, a pragmatic and robust method for MRD monitoring is urgently needed. Herein, a novel split-type electrochemical sensor (E-sensor) was developed by integrating nucleic acid sequence-based amplification (NASBA) with enzyme-linked magnetic microbeads (MMBs) for ultra-sensitive detection of the PML/RARα transcript.

View Article and Find Full Text PDF

Importance: Atrial fibrillation (AF) is the most common, chronic, cardiac arrythmia in older US adults. It is not known whether AF is independently associated with increased risk of retinal stroke (central retinal artery occlusion), a subtype of ischemic stroke that causes severely disabling visual loss in most cases and is a harbinger of further vascular events.

Objective: To determine whether there is an association between AF and retinal stroke.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!